Relation and regulatory mechanism between the concentration of Imatinib in bone marrow cells and the

来源 :广东省医学会第十七次血液病学学术会议 | 被引量 : 0次 | 上传用户:cjz8290911
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: To determine the relationship of Imatinib (IM) concentration in bone marrow and its therapeutic response in patients with chronic myelogenous leukemia in China.To explore the underlying mechanism.Method: 90 patients enrolled were all diagnosed with chronic myelogenous leukemia according to the guidelines of NCCN 2011, with 88 patients in chronic phase (CP) and 2 in accelerated phase (AC).The median age was 40 years (range from 11 to 77 years).All diagnostic patients had received IM treatment at the dosage of 400mg (range from 300 to 800mg) for 30 months (range 1 to 117 months).Bone marrow mononuclear cells were collected 0.5 hour before IM administration in order to test the expression of Bcr/abl by using FISH and RQ-PCR, the mRNA expression of hOCT1and ABCB1 by QRT-PCR and the gene polymorphism of ABCB1 on C1236T, C3435T and G2677T.IM concentration in bone marrow mononuclear cells was measured by a method of liquid chromatography in tandem with mass spectrometr.We then analyzed IM concentration, expression of hOCT1 and ABCB1 and their relationship with therapeutic response.Result: In 61 patients with CCR, the mRNA expression of ABCB1 (88.05, range from 3.3 to 1558.8) was significantly lower than that of 17 patients in resistant group (102, range from 11.3 to 1604.9, p < 0.01) and 17 in PCyR group (33.1, range from 2.2 to 108.2, p < 0.01).On the other hand, the mRNA expression of hOCT1 was significantly higher in CCR group (16.6, range 1.7 to 199.8) as compared with that in drug-resistant group (10.1, range from 0.7 to 33.5, p < 0.01) and PCyR group (5.9, range from 1.4 to 30.3, p < 0.01).IM concentration was found to be positively associated with the mRNA expression of hOCT1 (r=0.456, p=0.033) and has negatively associated with the mRNA expression of ABCB1 (r=-0.491,p=0.015).Data from the gene polymorphism of ABCB1 indicated that in 48 patients with mRNA expression of ABCB1 above the median level, and patients without CCR had a significant higher frequency of T alleles than C on C1236T (x2=4, P=0.046), while C and G higher than T on C3435T (x2=7.11, p < 0.01) and C2677T (x2=5.44, p < 0.01) respectively.Conclusion: IM concentration in bone marrow cells is regulated by hOCT1 and ABCB1 and they promisingly affect the therapeutic response.
其他文献
未足月胎膜早破(PPROM)妊娠未满37周胎膜在临产前发生破裂.单胎PPROM 2%-4%,双胎7%-20%多数在破膜后1周内分娩双胎的临产潜伏期更短PPROM占单胎早产分娩1/3,占双胎早产分娩1/10未足月胎膜早破(PPROM)概述
会议
国内产科特点独生子多.大多数对孩子质量要求高,特殊人群可接受有一定瑕疵的孩子.对胎儿关注仍不够,需要胎儿医学科.畸形发生率在一些地区和人群中仍较高.法律.B超有局限—强烈建议孕妇常规行胎儿MRI检查开展胎儿宫内发育研究和诊断-受精卵质量、宫内发育成长监控、胎儿生产过程无创.
会议
目的 总结胎儿隔离肺(BPS)的产前评估和诊治经验。方法 回顾分析本院2010年5月至2013年1月产前诊断咨询的BPS胎儿资料,通过超声检查确定诊断,结合胎儿肺头比(CVR)的测定,进行专业评估和记录孕妇和胎儿的诊疗资料,出生后的进一步跟踪,并在新生儿或婴幼儿期手术治疗及随访。
会议
目的 探讨三例复发性流产患者外周血的基因芯片检测结果分析。方法 利用博奥生物染色体异常检测基因芯片对三例复发性流产患者的外周血进行检测,并进行初步分析。
会议
背景 侧脑室增宽为染色体异常常见的软指标,也是产前超声中常见的胎儿异常,不合理的咨询及处理给孕妇及家人带来极大的恐慌及担忧.目的 研究侧脑室增宽胎儿的染色体异常发生率,及侧脑室增宽与不良妊娠结局的关系;方法回顾本院2009年1月至2012年9月共127例单一侧脑室增宽(10mm-15mm)胎儿的产前诊断情况,并追踪随访所有胎儿的妊娠结局;结果 127例侧脑室增宽胎儿中35例行产前诊断查染色体(27
会议
This study evaluated the feasibility, safety, and immunological effects of intravenous administration of haploidentical mesenchymal stem cells (MSCs) in patients with relapse/refractory aplastic anemi
目的:探讨APP基因对t(8; 21)异常AML患者预后影响及在髓外浸润中的作用机制.方法:(1)研究对象为南方医院2006年2月至2012年2月间经FISH或骨髓染色体培养法诊断的44例伴t (8; 21) AML患者(男∶女=25∶15,中位年龄29岁).①QRT-PCR法检测初发病时骨髓APP mRNA表达量(western blot法核实),≥中位表达量为高表达组(n=22),否则为低表达
会议
目的:异基因造血干细胞移植(allo-HSCT)是根治难治未缓解急性白血病的最有效方法,但标准预处理方案移植后复发率高达50%,3年总生存率(OS)仅为7%-13%.我们前期研究采用超强预处理联合早期快速减免免疫抑制剂,使难治白血病患者3年OS提高至44.6%±8.1%,但3年累积复发率仍高达33.3%.
目的:分析真核细胞翻译起始因子4E(eIF4E)在急性髓系白血病(AML)患者不同亚型以及在初诊未治疗、治疗后完全缓解、治疗后未缓解/缓解后复发等状态下骨髓细胞中的表达变化和其与细胞周期调节相关的蛋白cyclin D1 (CCND1)、c-myc mRNA的表达的相关性,分析患者临床参数对eIF4E、CCND1和c-myc表达的影响.方法:收集经临床、细胞形态、免疫表型分析及细胞遗传学确诊、按FA
会议
Background: Imatinib is capable of inducing durable molecular responses in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but it is in